Tumors derived from a hormonal target organ are assumed to be stimulated by the same hormone that stimulates the normal target tissue. In spite of attempts to acquire direct indications of a correlation between hormones and cancer, none have been definitive because studies of total and free hormone levels have given contradictory results. For this reason, attention has shifted to the study of plasma binding and transport of hormones, that is, of the proteins responsible for modulation of the hormone effect and thus of hormone bioavailability. The data reviewed indicate that in-depth study of the transport and binding system of sex steroids would give new information about the endocrine characteristics of cancer patients.
AntunesC.M.F., StolleyP.D., RosensheinN.B., DaviesJ.L., TonasciaJ.A., BrownC., BurnettL., RutledgeA., PokempnerM., GarciaR.: Endometrial cancer and estrogen use - report of a large case control study. N. Engl. J. Med., 300: 9–13, 1979.
3.
BiffignandiP., MassucchettiC., MolinattiG.M.: Il trasporto plasmatico e la recettorialità periferica degli ormoni androgeni. In: Andrologia e fisiopatologia della riproduzione.MolinattiG.M., CamanniS. (Eds.), pp. 115–131. Field Educational Italia. Acta Medica, Roma, 1984.
4.
BigazziU.: Aspetti genetici delle endocrinopatie. Federazione Medica, 38: 296–302, 1985.
5.
BondA., DavisC.: Sex hormone binding globulin in clinical perspective. Acta Obstet. Gynecol. Scand., 66: 255–262, 1987.
6.
BonneyR.C., ReedM.J., JamesV.H.T.: Inhibition of 17beta-hydroxysteroid dehydrogenase activity in human endometrium by adrenal androgens. J. Steroid. Biochem., 18: 59–64, 1983.
7.
BrodyS., CarlstromK., LagreliusA., LunellN.O., MollerstromG., PousetteA.: Serum sex hormone binding globulin (SHBG), testosterone/SHBG index, endometrial pathology and bone mineral density in postmenopausal women. Acta Obstet. Gynecol. Scand., 66: 357–360, 1987.
8.
BruningP.F., Bonfre'rJ.M.G., HartA.A.M.: Non protein bound estradiol, sex hormone binding globulin, breast cancer and breast cancer risk. Br. J. Cancer, 51: 479–484, 1985.
9.
CorvolP.L., ChrambachA., RodbardD., BardinC.W.: Physical properties and binding capacity of testosterone-estradiol binding globulin in human plasma, determined by polyacrilamide gel electrophoresis. J. Biol. Chem., 246: 3435–3443, 1971.
10.
DavidsonB.J., GamboneJ.C., LagasseL.D., CastaldoT.W., HammondG.L., SiiteriP.K., JuddH.L.: Free estradiol in post-menopausal women with and without endometrial cancer. J. Clin. Endocrinol Metab., 52: 404–408, 1981.
11.
DemopoulosR.I.: Carcinoma of the endometrium. In: Pathology of the Female Genital Tract, pp. 278–298, Springer, New York, Heidelberg, Berlin, 1977.
12.
GrassoM., BuonaguidiA., MondinaR., BorsellinoG., LaniaC., BanfiG., RigattiP.: Plasma sex hormone binding globulin in patients with prostatic carcinoma. Cancer, 66: 354–358, 1990.
13.
GusbergS.B., KardonP.: Proliferative endometrial response to theca-granulosa cell tumors. Am. J. Obstet. Gynecol., 111: 633–643, 1971.
14.
GusbergS.B.: The individual at high risk for endometrial carcinoma. Am. J. Obstet. Gynecol., 126: 535–542, 1976.
15.
HaapiainenR., RannikkoS., AdlercreutzH., AlfthanO.: Correlation of pretreatment plasma levels of estradiol and sex-hormone-binding globulin-binding capacity with clinical stage and survival of patients with prostatic cancer. Prostate, 8: 127–137, 1986.
16.
HanssonV., LarsonJ., ReuschE.: Physiochemical properties of the 5-alpha-dihydrotestosterone binding protein in human serum. Steroids, 20: 555–574, 1972.
17.
HoughtonA.L., TurnerR., CooperE.H.: Sex hormone binding globulin in carcinoma of prostate. Br. J. Urol., 49: 227–232, 1977.
18.
HulkaB.S., HammondJ.E., DiFerdinandoG., MickeyD.D., FriedF.A., CheckowayH., StumpfW.E., BeckmanW.C.Jr., ClarkT.D.: Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls. Prostate, 11: 171–182, 1987.
19.
JacksonR.L., DockertyM.B.: The Stein-Leventhal syndrome: Analysis of 43 cases, with special reference to association with endometrial carcinoma. Am. J. Obstet. Gynecol., 73: 161–166, 1957.
20.
KarrJ.P., WajsmanZ., KirdaniR.Y., MurphyG.P., SandbergA.A.: Effects of diethylstilbestrol estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients. J. Urol., 124: 232–236, 1980.
21.
KorenmanS.G.: The endocrinology of breast cancer. Cancer, 46: 874–878, 1980.
22.
LoblT.J.: Androgen transport proteins: physical properties, hormonal regulation, and possible mechanism of TeBg and ABP action. Arch. Androl., 7: 133–151, 1981.
23.
MeikleA.W., SmithJ.A., StringlamJ.D.: Production, clearance and metabolism of testosterone in men with prostate cancer. Prostate, 10: 25–31, 1987.
24.
Mercier-Bodard: Sex-steroid binding plasma protein (SBP) and steroid-hormone-related cancers. In: Binding Proteins of Steroid Hormones.ForestM.G., PugeatM. (Eds.), pp. 455–469. Les Editions Inserm; John Lippey Eurotext, London-Paris, 149: 1986.
MondinaR., BorsellinoG., PirondiniA., BaroniM., SecchiG., PomaS., PellegriniG.: Breast carcinoma and 17beta-estradiol binding. Cancer, 63: 305–308, 1989.
27.
MooreJ.W., ClarkG.M., BulbrookR.D., HaywardJ.L., MuraiJ.T., HammondG.L., SiiteriP.K.: Serum concentrations of total and non-protein-bound oestradiol in patients with breast cancer and in normal controls. Int. J. Cancer, 29: 17–21, 1982.
28.
MurayamaY., UtsonomiyaJ., TakahashiI., KitamuraM., TominagaT.: Sex hormone binding globulin, breast cancer and breast cancer risk. Ann. Surg., 190: 133–138, 1979.
29.
NiskerJ.A., HammondG.L., DavidsonB.J., FrumarA.M., TakakiN.K., JuddH.L., SiiteriP.K.: Serum sex hormone-binding globulin capacity and the percentage of free estradiol in post-menopausal women with and without endometrial carcinoma. Am. J. Obstet. Gynecol., 138: 637–642, 1980.
30.
NiskerJ.A., RamzyI., CollinsJ.A.: Adenocarcinoma of the endometrium and abnormal ovarian function in young women. Am. J. Obstet. Gynecol., 130: 546–550, 1978.
31.
O'MalleyB.W.: Mechanisms of action of steroid hormones. N. Engl. J. Med., 284: 370–377, 1971.
32.
PardridgeW.M., MietusL.J.: Transport of protein bound steroid hormones into liver in vivo. Am. J. Physiol., 237: E367–E372, 1979.
33.
PasqualiniJ.R.: Hormonal regulation of the prostate gland: Physiology and pathology. Triangle, 21: 21–26, 1982.
34.
ReedM.J., ChengR.W., NoelC.T., DudleyH.A.F., JamesV.H.T.: Plasma levels of estrone, estrone sulfate, and estradiol and the percentage of unbound estradiol in postmenopausal women with and without breast disease. Cancer Res., 43: 3940–3943, 1983.
35.
SiiteriP.K., MuraiJ.T., HammondG.L., NiskerJ.A., RaymoureW.J., KuhnR.W.: The serum transport of steroid hormones. Recent Prog. Horm. Res., 38: 457–510, 1982.
36.
SiiteriP.K.: Plasma steroid-binding proteins - past, present and future. In: Binding Proteins of Steroid Hormones.ForestM.G., PugeatM. (Eds)., pp. 593–610, Les Editions Inserm, John Lippey Eurotext, London-Paris, 149: 1986.
37.
SulkesA., FuksZ., GordonA., GrossJ.: Sex hormone binding globulin (SHBG) in breast cancer. A correlation with obesity but not with estrogen receptor status. Eur. J. Cancer. Clin. Oncol., 20: 19–23, 1984.
38.
TrichopulosD.: Hypothesis: does breast cancer originate in utero?Lancet, 335: 939–940, 1990.
39.
Van BaelenH., HeynesW., SchonneE., deMoorP.: An estradiol binding globulin in human serum: partial purification. Ann. Endocrinol., 29: Supplement; 153–159, 1968.
40.
van KeepP.A., LauritzenC.: Estrogen in the Postmenopause. Front. Horm. Res., 3: 40–44, 1975.
41.
WayS.: The aetiology of carcinoma of the body of the uterus. J. Obstet. Gynecol. Br. Empire, 61: 46–54, 1954.
42.
WilsonE.A., JawadM.J., DonaldsonE.S.: Corticosteroid-binding globulin as a biologic assay for endogenous estrogen in patients with and without endometrial carcinoma. Am. J. Obstet. Gynecol., 139: 661–664, 1981.
43.
ZiehlH.K., FinckleW.D.: Increased risk of endometrial carcinoma among users of conjugated estrogens. N. Engl. J. Med., 293: 1167–1170, 1975.
